Current status of adoptive immunotherapy of malignancies

被引:23
作者
Morse, MA
Clay, TM
Lyerly, HK
机构
[1] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
关键词
adoptive immunotherapy; cytotoxic T-cells; T-cell receptor;
D O I
10.1517/14712598.2.3.237
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Adoptive immunotherapy involves the transfer of immune effectors with antitumour activity into the tumour bearing host. Early approaches such as lymphokine activator killer (LAK) cells and tumour infiltrating lymphocytes (TILs) have yielded occasional clinical responses, More recently, attempts to stimulate and/or select antigen-specific T-cells in vitro have demonstrated that tumour-specific adoptive immunotherapy is possible. These approaches require complicated and time consuming in vitro stimulation procedures. Therefore, genetic modification of bulk T-cell populations is an attempt to create a large population of T-cells with a single specificity. In addition to work being done to develop the most potent effector, other studies are working on improving T-cell trafficking to tumours and interfering with the tumour-induced immunosuppression that can impair in vivo T-cell activity.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 92 条
[51]  
Molldrem JJ, 1999, CANCER RES, V59, P2675
[52]   Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy [J].
Montagna, D ;
Maccario, R ;
Locatelli, F ;
Rosti, V ;
Yang, Y ;
Farness, P ;
Moretta, A ;
Comoli, P ;
Montini, E ;
Vitiello, A .
BLOOD, 2001, 98 (12) :3359-3366
[53]   CYTOTOXIC T-LYMPHOCYTES WITH A GRAFTED RECOGNITION SPECIFICITY FOR ERBB2-EXPRESSING TUMOR-CELLS [J].
MORITZ, D ;
WELS, W ;
MATTERN, J ;
GRONER, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4318-4322
[54]  
Mukherjee P, 2001, CLIN CANCER RES, V7, p848S
[55]  
Oelke M, 2000, CLIN CANCER RES, V6, P1997
[56]   EFFECT OF AUTOLYMPHOCYTE THERAPY ON SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA [J].
OSBAND, ME ;
LAVIN, PT ;
BABAYAN, RK ;
GRAHAM, S ;
LAMM, DL ;
PARKER, B ;
SAWCZUK, I ;
ROSS, S ;
KRANE, RJ .
LANCET, 1990, 335 (8696) :994-998
[57]   T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance [J].
Phan, GQ ;
Wang, E ;
Marincola, FM .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (03) :511-523
[58]   Immunotherapy of metastatic kidney cancer [J].
Pizza, G ;
De Vinci, C ;
Lo Conte, G ;
Maver, P ;
Dragoni, E ;
Aiello, E ;
Fornarola, V ;
Bergami, T ;
Busutti, L ;
Boriani, S ;
Palareti, A ;
Capanna, R .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (01) :109-120
[59]   Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells [J].
Plautz, GE ;
Touhalisky, JE ;
Shu, SY .
CELLULAR IMMUNOLOGY, 1997, 178 (02) :101-107
[60]   T-cell adoptive immunotherapy of metastatic renal cell carcinoma [J].
Plautz, GE ;
Bukowski, RM ;
Novick, AC ;
Klein, EA ;
Kursh, ED ;
Olencki, TE ;
Yetman, RJ ;
Pienkny, A ;
Sandstrom, K ;
Shu, SY .
UROLOGY, 1999, 54 (04) :617-623